“incyte” Archives

in
Entry Author Date Location
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More 10/09/20 National
Kinnate Raises $98M for Human Tests of Targeted Cancer Therapies 08/26/20 San Francisco
Advisory Body Backs MesoBlast Therapy for Transplant Complication 08/14/20 New York
Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More 08/07/20 National
MorphoSys, Incyte Get Early FDA Nod for Antibody Alternative to CAR-T 08/03/20 Europe
Bio Roundup: Jazz Drug OK’d, Gilead’s Bet, Moderna Patent Decision & More 07/24/20 National
Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More 05/08/20 National
Novartis Drug Wins FDA Approval for Lung Cancers With Specific Mutation 05/06/20 National
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More 04/24/20 National
FDA Approves Incyte Drug, First Ever for Rare Bile Duct Cancer 04/20/20 National
Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More 02/14/20 National
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More 01/31/20 National
Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More 01/17/20 National
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug 01/13/20 National
With FDA’s Eye on JAK Drugs, Concert Moves One Ahead For Hair Loss 09/03/19 Boston
AACR 2019 Roundup: Notes from a Weekend of Early Stage Cancer Results 04/03/19 National
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More 02/08/19 National
Despite Buyout, Celgene Dealmaking Rolls On With Kyn, Obsidian Tie-Ups 01/18/19 Boston
Merck And The Future of Immuno-Oncology: A Chat With Roger Perlmutter 01/16/19 National
Sierra Oncology Acquires Gilead’s Stalled Myelofibrosis Drug 08/22/18 Seattle
Benchling Scores $14.5M to Grow Online Lab Notebook for Bio-Researchers 06/14/18 San Francisco
Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning 06/01/18 Indiana
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More 06/01/18 National
IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down 05/31/18 National
With $1.6B Armo Buy, Eli Lilly Is the Latest to Bet Big on Cytokines 05/10/18 Indiana
Roche-Exelixis Study Fails as Mixed Year Continues For Cancer Drug Combos 05/10/18 San Francisco
Bio Roundup: IDO Fallout, Express Scripts Dumps Amgen, Isaly Out & More 05/04/18 National
Bristol-Myers Latest to Drop IDO Studies in Wake of Incyte Failure 04/30/18 New York
FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses 04/23/18 Indiana
Safety Concerns Linger for Lilly’s Arthritis Drug as FDA Panel Looms 04/19/18 Indiana
Page 1 of 3 next page »